A Comprehensive Guide to Sodium Glucose Cotransport Inhibitors

Christopher Cunningham; Ahmad Jabri; Laith Alhuneafat; Ashish Aneja

doi:10.1016/j.cpcardiol.2023.101817

A Comprehensive Guide to Sodium Glucose Cotransport Inhibitors

Curr Probl Cardiol. 2023 Oct;48(10):101817. doi: 10.1016/j.cpcardiol.2023.101817. Epub 2023 May 19.

Authors

Christopher Cunningham¹, Ahmad Jabri², Laith Alhuneafat³, Ashish Aneja⁴

Affiliations

¹ Department of Medicine, The MetroHealth System, Cleveland, OH.
² Department of Cardiovascular Disease, Henry Ford, Detroit, Michigan, USA. Electronic address: jabri.ahmad91@gmail.com.
³ Department of Medicine, Allegheny Health Network, Pittsburgh, PA.
⁴ Heart and Vascular Division, The MetroHealth System, Cleveland, OH.

PMID: 37211299
DOI: 10.1016/j.cpcardiol.2023.101817

Abstract

Sodium-glucose cotransport 2 inhibitors (SGLT2i) are a class of drugs initially approved by the Food and Drug Association (FDA) as antihyperglycemic agents for patients with type 2 diabetes mellitus (DM). However, lately, these agents (Canagliflozin, Empagliflozin, Ertugliflozin, Sotagliflozin, and Dapagliflozin) have become better known for their cardiovascular (CV) and reno-protective effects. In this comprehensive review and analysis, we display the advancement of Sodium Glucose Cotransport Inhibitors have shown in cardiology, specifically heart failure in a concise, yet thorough manner.

Publication types

Review

MeSH terms

Cardiovascular Diseases* / drug therapy
Diabetes Mellitus, Type 2* / drug therapy
Glucose
Humans
Hypoglycemic Agents / pharmacology
Hypoglycemic Agents / therapeutic use
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors
Glucose
Hypoglycemic Agents